Overview
C the Signs uses artificial intelligence to help healthcare professionals detect cancer earlier by analyzing patient symptoms, clinical data, and risk factors to suggest diagnostic and referral pathways. The platform runs in real time and integrates into primary care and health system workflows, giving clinicians guidance on tests, referrals, and next steps across all cancer types. It differentiates itself by providing real-time decision support in primary care, broad cancer coverage including rare cancers, and population-health insights that identify disparities and streamline referrals. Its goal is to improve patient outcomes through earlier diagnosis, faster access to diagnostic pathways, and scalable, personalized cancer care.
Work here?Claim your company
Simplify's take
What believers are saying
- January 2026 Suffolk ICB results showed 808% ROI and £1.5 million savings.
- June 2026 North East Essex launched AI pathways for oesophageal and stomach cancers.
- Khosla-backed $8 million financing supports U.S. entry and broader system partnerships.
What critics are saying
- NHS procurement concentration leaves revenue exposed if ICB rollouts stall in 2027.
- Independent evidence remains UK-centric; U.S. expansion still lacks published deployment data.
- Competing NHS AI triage tools can commoditize pathway guidance and compress pricing quickly.
What makes C the Signs unique
- Integrated into GP workflows, not a standalone screener, across 1,500+ practices.
- Analyzes 1,000+ evidence points and returns referral guidance under 60 seconds.
- Built by NHS doctors, with Class I medical-device status and 100+ cancer coverage.
Help us improve and share your feedback! Did you find this helpful?